Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Buy
58
NVZMY Quote, Financials, Valuation and Earnings
Last price:
$64.08
Seasonality move
:
3.38%
Day range:
$63.09 - $65.25
52-week range:
$53.95 - $75.99
Dividend yield:
1.5%
P/E ratio:
57.85x
P/S ratio:
7.11x
P/B ratio:
2.66x
Volume:
22.7K
Avg. volume:
54K
1-year change:
11.79%
Market cap:
$29.8B
Revenue:
$4.1B
EPS (TTM):
$1.14
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Novonesis (Novozymes A/S) has -- downside to fair value with a price target of -- per share.
NVZMY vs. S&P 500
-
Over the past 5 trading days, Novonesis (Novozymes A/S) has underperformed the S&P 500 by -0.27% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Novonesis (Novozymes A/S) does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novonesis (Novozymes A/S) revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Novonesis (Novozymes A/S) reported revenues of $1.2B.
Earnings Growth
-
Novonesis (Novozymes A/S) earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Novonesis (Novozymes A/S) reported earnings per share of $0.35.
Enterprise value:
33B
EV / Invested capital:
--
Price / LTM sales:
7.11x
EV / EBIT:
48.06x
EV / Revenue:
7.97x
PEG ratio (5yr expected):
1.34x
EV / Free cash flow:
46.24x
Price / Operating cash flow:
41.24x
Enterprise value / EBITDA:
25.89x
Gross Profit (TTM):
$2.6B
Return On Assets:
3.97%
Net Income Margin (TTM):
9.96%
Return On Equity:
6.56%
Return On Invested Capital:
5.02%
Operating Margin:
25.59%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.6B | -- | -- | -- | $1.2B | |
| Gross Profit | $1.4B | -- | -- | -- | $635.7M | |
| Operating Income | $610.3M | -- | -- | -- | $228.8M | |
| EBITDA | $620.1M | -- | -- | -- | $400M | |
| Diluted EPS | $1.65 | -- | -- | -- | $0.35 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1B | $1.2B | $1.3B | -- | $2.3B | |
| Total Assets | $3.4B | $3.7B | $4.1B | -- | $19.2B | |
| Current Liabilities | $687.8M | $954.4M | $883.5M | -- | $1.4B | |
| Total Liabilities | $1.6B | $1.8B | $1.9B | -- | $6.5B | |
| Total Equity | $1.8B | $1.9B | $2.1B | -- | $12.6B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $544.9M | -- | -- | -- | $542.9M | |
| Cash From Investing | -$360.8M | -- | -- | -- | -$248.5M | |
| Cash From Financing | -$198.8M | -- | -- | -- | -$348.7M | |
| Free Cash Flow | $193.9M | -- | -- | -- | -- | |
NVZMY
Sector
Market Cap
$29.8B
$22.5M
Price % of 52-Week High
84.08%
71.92%
Dividend Yield
1.5%
0%
Shareholder Yield
0.6%
-2.68%
1-Year Price Total Return
10.71%
13.68%
Beta (5-Year)
1.085
0.619
Dividend yield:
1.5%
Annualized payout:
$0.58
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$63.42
200-day SMA
Sell
Level
$64.73
Bollinger Bands (100)
Buy
Level
60.97 - 64.41
Chaikin Money Flow
Buy
Level
8M
20-day SMA
Buy
Level
$62.48
Relative Strength Index (RSI14)
Buy
Level
59.38
ADX Line
Buy
Level
10.94
Williams %R
Neutral
Level
-39.3657
50-day SMA
Buy
Level
$62.47
MACD (12, 26)
Buy
Level
0.44
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
4.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.4503)
Buy
CA Score
(Annual)
Level (0.6739)
Sell
Beneish M-Score
(Annual)
Level (-1.4516)
Sell
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-1.9316)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Novonesis (Novozymes A/S) engages in the era of biosolutions. It innovate and develop transformative biosolutions that improve the way the world produces, consumes, and lives. The company was founded on January 29, 2024 is headquartered in Lyngby, Denmark.
Stock Forecast FAQ
In the current month, NVZMY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NVZMY average analyst price target in the past 3 months is --.
-
Where Will Novonesis (Novozymes A/S) Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novonesis (Novozymes A/S) share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Novonesis (Novozymes A/S)?
Analysts are divided on their view about Novonesis (Novozymes A/S) share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Novonesis (Novozymes A/S) is a Sell and believe this share price will rise from its current level to --.
-
What Is Novonesis (Novozymes A/S)'s Price Target?
The price target for Novonesis (Novozymes A/S) over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NVZMY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novonesis (Novozymes A/S) is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NVZMY?
You can purchase shares of Novonesis (Novozymes A/S) via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novonesis (Novozymes A/S) shares.
-
What Is The Novonesis (Novozymes A/S) Share Price Today?
Novonesis (Novozymes A/S) was last trading at $64.08 per share. This represents the most recent stock quote for Novonesis (Novozymes A/S). Yesterday, Novonesis (Novozymes A/S) closed at $64.08 per share.
-
How To Buy Novonesis (Novozymes A/S) Stock Online?
In order to purchase Novonesis (Novozymes A/S) stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get NVZMY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NVZMY
Sector
P/E ratio
57.85x
19.47x
PEG ratio
1.34x
-0.02x
P/B ratio
2.66x
1.73x
Price / LTM sales
7.11x
1.56x
Growth Metrics
NVZMY
Sector
Revenue growth
-13.35%
2.23%
Earnings growth
-50.53%
--
Revenue (5-year growth)
13.99%
3.12%
Earnings forecast
--
$0.02
Profitability
NVZMY
Sector
Profitability FY 2024
$1.8B
--
Return on invested capital
5.02%
-8.83%
Return on assets
3.97%
-9.87%
Return on equity
6.56%
-9.61%
Earnings Date
Last Earnings Date
Aug
21
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Nov
20
Balance Sheet
NVZMY
Sector
Total cash
$363.7M
$2.6M
Short term investments
$4.2M
$229.2K
Total assets
$16.8B
$16.9M
Long term debt
$1.8B
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
89
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 18.81% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Buy
72
GLTO alert for Dec 30
Galecto, Inc. [GLTO] is down 12.13% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
